10-propargyl-10-deazaaminopterin has been researched along with epirubicin in 2 studies
Studies (10-propargyl-10-deazaaminopterin) | Trials (10-propargyl-10-deazaaminopterin) | Recent Studies (post-2010) (10-propargyl-10-deazaaminopterin) | Studies (epirubicin) | Trials (epirubicin) | Recent Studies (post-2010) (epirubicin) |
---|---|---|---|---|---|
119 | 21 | 85 | 5,453 | 1,838 | 1,570 |
Protein | Taxonomy | 10-propargyl-10-deazaaminopterin (IC50) | epirubicin (IC50) |
---|---|---|---|
Genome polyprotein | 0.75 | ||
Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.181 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Advani, RH; Ansell, SM; Beaven, AW; Carson, KR; Evens, AM; Foss, F; Horwitz, S; Lechowicz, MJ; Loberiza, F; Pinter-Brown, LC; Pro, B; Savage, KJ; Shustov, AR; Smith, SM; Vose, JM | 1 |
1 review(s) available for 10-propargyl-10-deazaaminopterin and epirubicin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for 10-propargyl-10-deazaaminopterin and epirubicin
Article | Year |
---|---|
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 2016 |